PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
종목 코드 PMCB
회사 이름PharmaCyte Biotech Inc
상장일Sep 11, 2003
CEOMr. Joshua N. (Josh) Silverman
직원 수2
유형Ordinary Share
회계 연도 종료Sep 11
주소3960 Howard Hughes Parkway, Suite 500
도시LAS VEGAS
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호89169
전화19175952850
웹사이트https://pharmacyte.com/
종목 코드 PMCB
상장일Sep 11, 2003
CEOMr. Joshua N. (Josh) Silverman
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음